Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Concordance of p16INK4a and E6*I mRNA among HPV-DNA-positive oropharyngeal, laryngeal, and oral cavity carcinomas from the ICO International Study

  • Mena, Marisa
  • Lloveras Rubio, Belen
  • Alemany, Laia
  • International Hpv In Head And Neck Cancer Study Group
Tests or test algorithms for diagnosing HPV-driven oral cavity and laryngeal head and neck carcinomas (HNC) have not been yet validated, and the differences among oral cavity and laryngeal sites have not been comprehensively evaluated. We aimed to assess the utility of a diagnostic algorithm for the detection of HPV-driven oral cavity (OCC), oropharyngeal (OPC) and laryngeal (LC) carcinomas using HPV-DNA testing followed by p16INK4a immunohistochemistry, taking E6*I mRNA detection as the reference standard. Methods: Formalin-fixed paraffin-embedded OCC, OPC, and LC carcinomas were collected from pathology archives in 29 countries. All samples were subjected to histopathological evaluation, DNA quality control, and HPV-DNA detection. All HPV-DNA-positive samples (including 78 OCC, 257 OPC, and 51 LC out of 3680 HNC with valid HPV-DNA results) were also tested for p16INK4a immunohistochemistry and E6*I mRNA. Three different cutoffs of nuclear and cytoplasmic staining were evaluated for p16INK4a: (a) >25%, (b) >50%, and (c) ≥70%. The concordance of p16INK4a and E6*I mRNA among HPV-DNA-positive OCC, OPC, and LC cases was assessed. Results: A total of 78 OCC, 257 OPC, and 51 LC were HPV-DNA-positive and further tested for p16INK4a and E6*I mRNA. The percentage of concordance between p16INK4a (cutoff ≥ 70%) and E6*I mRNA among HPV-DNA-positive OCC, OPC, and LC cases was 79.5% (95% CI 69.9–89.1%), 82.1% (95% CI 77.2–87.0%), and 56.9% (95% CI 42.3–71.4%), respectively. A p16INK4a cutoff of >50% improved the concordance although the improvement was not statistically significant. For most anatomical locations and p16INK4a cutoffs, the percentage of discordant cases was higher for HPV16- than HPV-non16-positive cases. Conclusions: The diagnostic algorithm of HPV-DNA testing followed by p16INK4a immunohistochemistry might be helpful in the diagnosis of HPV-driven OCC and OPC, but not LC. A different p16INK4a expression pattern was observed in those cases HPV-DNA-positive for types other than HPV16, as compared to HPV16-positive cases. Our study provides new insights into the use HPV-DNA, p16INK4a, and HPV-E6*I mRNA for diagnosing an HPV-driven HNC, including the optimal HPV test or p16INK4a cutoffs to be used. More studies are warranted to clarify the role of p16INK4a and HPV status in both OPC and non-OPC HNC., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This study was funded by Instituto de Salud Carlos III through the projects FIS PI081535, FIS PI1102096, FIS PI1102104, and CIBERESP CB06/02/007 (co-funded by European Regional Development Fund (ERDF), a way to build Europe), by the Agència de Gestió d’Ajuts Universitaris I de Recerca AGAUR (2017SGR1085), and by the AECC (Spanish Association Against Cancer). The research leading to these results received funding from the European Union’s Seventh Framework Program (FP7/2007-2013) under grant agreement n◦ HEALTH-F2-2011-282562 HPV-AHEAD, from the Stichting Pathologie Ontwikkeling en Onderzoek (SPOO) foundation (The Netherlands), and from Sanofi Pasteur MSD and Merck & Co, Inc.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer

  • Simoens, Cindy
  • Lloveras Rubio, Belen
  • Arbyn, Marc
  • HPV-AHEAD study group
Background: the incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. These considerations highlight the importance of reliable and accurate markers to diagnose truly HPV-induced OPC. Methods: the accuracy of three possible test strategies, i.e. (a) hrHPV DNA PCR (DNA), (b) p16(INK4a) immunohistochemistry (IHC) (p16), and (c) the combination of both tests (considering joint DNA and p16 positivity as positivity criterion), was analysed in tissue samples from 99 Belgian OPC patients enrolled in the HPV-AHEAD study. Presence of HPV E6*I mRNA (mRNA) was considered as the reference, indicating HPV etiology. Results: ninety-nine OPC patients were included, for which the positivity rates were 36.4%, 34.0% and 28.9% for DNA, p16 and mRNA, respectively. Ninety-five OPC patients had valid test results for all three tests (DNA, p16 and mRNA). Using mRNA status as the reference, DNA testing showed 100% (28/28) sensitivity, and 92.5% (62/67) specificity for the detection of HPV-driven cancer. p16 was 96.4% (27/28) sensitive and equally specific (92.5%; 62/67). The sensitivity and specificity of combined p16 + DNA testing was 96.4% (27/28) and 97.0% (65/67), respectively. In this series, p16 alone and combined p16 + DNA missed 1 in 28 HPV driven cancers, but p16 alone misclassified 5 in 67 non-HPV driven as positive, whereas combined testing would misclassify only 2 in 67. Conclusions: single hrHPV DNA PCR and p16(INK4a) IHC are highly sensitive but less specific than using combined testing to diagnose HPV-driven OPC patients. Disease prognostication can be encouraged based on this combined test result., The global HPV-AHEAD study was initially funded by the European Commission, with Grant Number: FP7-HEALTH-2011-282562. Sciensano, the employer of CS and MA, received funding for the analysis of the Belgian part of the HPV-AHEAD study, in part, by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. MA was also supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network (Grant No. 847845); and the Belgian Foundation Against Cancer through the IHUVACC project.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study

  • Mena, Marisa
  • Lloveras Rubio, Belen
  • Tous, Sara
  • Bogers, Johannes
  • Maffini, Fausto
  • Gangane, Nitin
  • Kumar, Rekha Vijay
  • Somanathan, Thara
  • Lucas, Eric
  • Anantharaman, Devasena
  • Gheit, Tarik
  • Castellsagué, Xavier
  • Pawlita, Michael
  • Sanjosé Llongueras, Silvia de
  • Alemany, Laia
  • Tommasino, Massimo
  • HPV-AHEAD study group
Worldwide use of formalin-fixed paraffin-embedded blocks (FFPE) is extensive in diagnosis and research. Yet, there is a lack of optimized/standardized protocols to process the blocks and verify the quality and presence of the targeted tissue. In the context of an international study on head and neck cancer (HNC)-HPV-AHEAD, a standardized protocol for optimizing the use of FFPEs in molecular epidemiology was developed and validated. First, a protocol for sectioning the FFPE was developed to prevent cross-contamination and distributed between participating centers. Before processing blocks, all sectioning centers underwent a quality control to guarantee a satisfactory training process. The first and last sections of the FFPEs were used for histopathological assessment. A consensus histopathology evaluation form was developed by an international panel of pathologists and evaluated for four indicators in a pilot analysis in order to validate it: 1) presence/type of tumor tissue, 2) identification of other tissue components that could affect the molecular diagnosis and 3) quality of the tissue. No HPV DNA was found in sections from empty FFPE generated in any histology laboratories of HPV-AHEAD consortium and all centers passed quality assurance for processing after quality control. The pilot analysis to validate the histopathology form included 355 HNC cases. The form was filled by six pathologists and each case was randomly assigned to two of them. Most samples (86%) were considered satisfactory. Presence of >50% of invasive carcinoma was observed in all sections of 66% of cases. Substantial necrosis (>50%) was present in <2% of samples. The concordance for the indicators targeted to validate the histopathology form was very high (kappa > 0.85) between first and last sections and fair to high between pathologists (kappa/pabak 0.21-0.72). The protocol allowed to correctly process without signs of contamination all FFPE of the study. The histopathology evaluation of the cases assured the presence of the targeted tissue, identified the presence of other tissues that could disturb the molecular diagnosis and allowed the assessment of tissue quality., unding Statement This study was supported by the European Commission, grant HPV-AHEAD (FP7-HEALTH-2011-282562), URLs: http://cordis.europa.eu/project/rcn/100268_es.html, All authors, Coordinator MT; Instituto de Salud Carlos III-ISCIII (Spanish Government) cofunded by FEDER funds / European Regional Development Fund (ERDF) - a way to build Europe (Reference: RD12/0036/0056), URLs: http://www.rticc.org/epidemiologia-prevencion-grupos.php#tech, MM, ST, BL, Coordinator Francesc Xavier Bosch.; Instituto de Salud Carlos III-ISCIII (Spanish Government) cofunded by FEDER funds / European Regional Development Fund (ERDF) - a way to build Europe (CIBERESP Group 36 CB06/02/0073), URLs: http://www.ciberesp.es/grupos/grupo-de-investigacion?id=12515, XC and LA, Coordinator SdS; Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR 2014SGR1077), URLs: http://agaur.gencat.cat/en/inici/index.html, XC, LA and ST, Coordinator Francesc Xavier Bosch.; Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR 2014SGR756), URLs: http://agaur.gencat.cat/en/inici/index.html, MM, Coordinator SdS.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Role of human papillomavirus infection in head and neck cancer in Italy: the HPV-AHEAD study

  • Tagliabue, Marta
  • Lloveras Rubio, Belen
  • Chiocca, Susanna
  • The Hpv-Ahead Study Group
Literature on the role of human papillomavirus (HPV) in head and neck cancer (HNC) in Italy is limited, especially for non-oropharyngeal tumours. Within the context of the HPV-AHEAD study, we aimed to assess the prognostic value of different tests or test algorithms judging HPV carcinogenicity in HNC and factors related to HPV positivity at the European Institute of Oncology. We conducted a retrospective cohort study (2000-2010) on a total of 696 primary HNC patients. Formalin-fixed, paraffin-embedded cancer tissues were studied. All HPV-DNA-positive and a random sample of HPV-DNA-negative cases were subjected to HPV-E6*I mRNA detection and p16INK4a staining. Multivariate models were used to assess for factors associated with HPV positivity and proportional hazards for survival and recurrence. The percentage of HPV-driven cases (considering HPV-E6*I mRNA positivity) was 1.8, 2.2, and 40.4% for oral cavity (OC), laryngeal (LC), and oropharyngeal (OPC) cases, respectively. The estimates were similar for HPV-DNA/p16INK4a double positivity. Being a non-smoker or former smoker or diagnosed at more recent calendar periods were associated with HPV-E6*I mRNA positivity only in OPC. Being younger was associated with HPV-E6*I mRNA positivity in LC. HPV-driven OPC, but not HPV-driven OC and LC, showed better 5 year overall and disease-free survival. Our data show that HPV prevalence in OPC was much higher than in OC and LC and observed to increase in most recent years. Moreover, HPV positivity conferred better prognosis only in OPC. Novel insights on the role of HPV in HNC in Italy are provided, with possible implications in the clinical management of these patients., This study was funded by European Commission HPV-AHEAD. Grant Number: FP7-HEALTH-2011–282562. This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 × 1000 funds. M. Ar. was supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network, Grant Number 847845. Research on HPV and Head and Neck Cancer in Susanna Chiocca laboratory was also supported by Associazione Italiana Ricerca sul Cancro (A.I.R.C. IG 2015 Id.16721).
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis

  • Mena Cervigón, Marisa
  • Taberna, Miren
  • Monfil, Laura
  • Arbyn, Marc
  • Sanjosé Llongueras, Silvia de
  • Bosch José, Francesc Xavier, 1947-
  • Alemany i Vilches, Laia
  • Bruni, Laia
Background. Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in depth. Methods. A systematic review was performed to identify studies in which at least 50 healthy individuals were tested for oral HPV infection. Information on sex, age, tobacco/alcohol consumption, sex practices, specimen collection, HPV detection, and population type was extracted. Prevalences were pooled using random-effects models for meta-analyses of binomial data. Correlations were assessed by the Spearman test. Results. Forty-eight reports comprising 28 544 individuals fulfilled inclusion criteria. Global oral HPV prevalence was 4.9%. Estimates were highest in Europe, although regional differences were not statistically significant. HPV16 prevalence was 1.0% globally, and regional differences became statistically significant. A lifetime history of >6 sex partners showed a higher risk of oral HPV infection. The age-specific HPV distribution revealed a prevalence of >= 5% over 40 years of age and a lower prevalence at younger ages. There was no association between oral HPV prevalence and HPV-AFs or age-standardized rates (ASRs) of OPC, genital HPV in healthy women, or tobacco use. Conclusions. Differences in HPV-AFs or ASRs of OPC cannot be explained by differences in the prevalence of oral HPV infection across healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence is warranted.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Comprehensive Control of Human Papillomavirus Infections and Related Diseases

  • Bosch José, Francesc Xavier, 1947-
  • Broker, Thomas R.
  • Forman, David
  • Moscicki, Anna-Barbara
  • Gillison, Maura L.
  • Doorbar, John
  • Stern, Peter L.
  • Stanley, Margaret
  • Arbyn, Marc
  • Poljak, Mario
  • Cuzick, Jack
  • Castle, Philip E.
  • Schiller, John T.
  • Markowitz, Lauri E.
  • Fisher, William A.
  • Canfell, Karen
  • Denny, Lynette A.
  • Franco, Eduardo L.
  • Steben, Marc
  • Kane, Mark A.
  • Schiffman, Mark
  • Meijer, Chris J. L. M.
  • Sankaranarayanan, Rengaswamy
  • Castellsagué, Xavier
  • Kim, Jane J.
  • Brotons, Maria
  • Alemany i Vilches, Laia
  • Albero, Ginesa
  • Diaz Sanchis, Mireia
  • Sanjosé Llongueras, Silvia de
Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread optimally universal implementation of HPV prevention strategies in both developed and developing countries. This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. (C) 2013 Elsevier Ltd. All rights reserved.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

  • Sanjosé Llongueras, Silvia de
  • Serrano, Beatriz
  • Tous, Sara
  • Alejo, Maria
  • Lloveras Rubio, Betlem
  • Quirós, Beatriz
  • Clavero, Omar
  • Vidal-Bel, August
  • Ferrándiz Pulido, Carla
  • Pavón Ribas, Miquel Àngel
  • Holzinger, Dana
  • Halec, Gordana
  • Tommasino, Massimo
  • Quint, Wim
  • Pawlita, Michael
  • Muñoz, Nubia
  • Bosch José, Francesc Xavier, 1947-
  • Alemany i Vilches, Laia
  • RIS HPV TT, VVAP and Head and Neck study groups
Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci- nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA- positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi- cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma

  • Baboci, Lorena
  • Boscolo-Rizzo, Paolo
  • Holzinger, Dana
  • Bertorelle, Roberta
  • Biasini, Lorena
  • Michel, Angelika
  • Schmitt, Markus
  • Spinato, Giacomo
  • Bussani, Rossana
  • Alemany i Vilches, Laia
  • Tirelli, Giancarlo
  • Mosto, Maria Cristina Da
  • Mistro, Annarosa Del
  • Pawlita, Michael
Persistent human papillomavirus infection (HPV) is recognized as an important etiologic factor for a subset of head and neck squamous cell carcinomas (SCC), especially those arising from the oropharynx. Whereas HPV16 accounts for the majority of HPV DNA-positive oropharyngeal SCC, infections with other mucosal high-risk HPV types are quite rare and biological data demonstrating their causal involvement are insufficient. Here we present the first case of an oropharyngeal SCC driven by HPV type 58. A 69-year-old Caucasian woman presented with an enlarged and firm left tonsil. A computed tomography scan showed a left tonsillar mass, extending to the soft palate and the glossotonsillar sulcus. The patient underwent extended radical tonsillectomy and ipsilateral selective neck dissection. Pathology confirmed an infiltrating, poorly differentiated SCC of the left tonsil with node metastasis (pT2N1). Adjuvant external beam radiation therapy (60 Grays (Gy)) was administered. After 1 year of follow-up, the patient is well with no evidence of cancer recurrence. HPV analyses of the tumor tissue by BSGP5+/6+-PCR/MPG, targeting 51 mucosal HPV types, showed single positivity for HPV type 58. Presence of HPV58 E6*I RNA demonstrated biological activity of the virus in the tumor tissue, and presence of serum antibodies to HPV58 oncoproteins E6 and E7 indicated presence of an HPV58-driven cancer. Overexpression of cellular protein p16(INK4a) and reduced expression of pRb, two cellular markers for HPV-induced cell transformation, were observed. Exons 4-10 of TP53 showed no mutations or polymorphisms. The presence of HPV58 as single HPV infection in combination with a broad variety of direct and indirect markers of HPV transformation provides comprehensive evidence that this oropharyngeal SCC was driven by HPV58.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study

  • Mena Cervigón, Marisa
  • Lloveras Rubio, Betlem
  • Tous, Sara
  • Bogers, Johannes
  • Maffini, Fausto
  • Gangane, Nitin
  • Kumar, Rekha Vijay
  • Somanathan, Thara
  • Lucas, Eric
  • Anantharaman, Devasena
  • Gheit, Tarik
  • Castellsagué, Xavier
  • Pawlita, Michael
  • Sanjosé Llongueras, Silvia de
  • Alemany i Vilches, Laia
  • Tommasino, Massimo
Worldwide use of formalin-fixed paraffin-embedded blocks (FFPE) is extensive in diagnosis and research. Yet, there is a lack of optimized/standardized protocols to process the blocks and verify the quality and presence of the targeted tissue. In the context of an international study on head and neck cancer (HNC)-HPV-AHEAD, a standardized protocol for optimizing the use of FFPEs in molecular epidemiology was developed and validated. First, a protocol for sectioning the FFPE was developed to prevent cross-contamination and distributed between participating centers. Before processing blocks, all sectioning centers underwent a quality control to guarantee a satisfactory training process. The first and last sections of the FFPEs were used for histopathological assessment. A consensus histopathology evaluation form was developed by an international panel of pathologists and evaluated for four indicators in a pilot analysis in order to validate it: 1) presence/type of tumor tissue, 2) identification of other tissue components that could affect the molecular diagnosis and 3) quality of the tissue. No HPV DNA was found in sections from empty FFPE generated in any histology laboratories of HPV-AHEAD consortium and all centers passed quality assurance for processing after quality control. The pilot analysis to validate the histopathology form included 355 HNC cases. The form was filled by six pathologists and each case was randomly assigned to two of them. Most samples (86%) were considered satisfactory. Presence of >50% of invasive carcinoma was observed in all sections of 66% of cases. Substantial necrosis (>50%) was present in <2% of samples. The concordance for the indicators targeted to validate the histopathology form was very high (kappa > 0.85) between first and last sections and fair to high between pathologists (kappa/pabak 0.21-0.72). The protocol allowed to correctly process without signs of contamination all FFPE of the study. The histopathology evaluation of the cases assured the presence of the targeted tissue, identified the presence of other tissues that could disturb the molecular diagnosis and allowed the assessment of tissue quality.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

  • Sanjosé Llongueras, Silvia de
  • Serrano, Beatriz
  • Tous, Sara
  • Alejo, Maria
  • Lloveras Rubio, Betlem
  • Quirós, Beatriz
  • Clavero, Omar
  • Vidal-Bel, August
  • Ferrándiz Pulido, Carla
  • Pavón Ribas, Miquel Àngel
  • Holzinger, Dana
  • Halec, Gordana
  • Tommasino, Massimo
  • Quint, Wim
  • Pawlita, Michael
  • Muñoz, Nubia
  • Bosch José, Francesc Xavier, 1947-
  • Alemany i Vilches, Laia
  • RIS HPV TT, VVAP and Head and Neck study groups
Background: Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vacci- nation programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. Methods: In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA- positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16INK4a immunohistochemistry. For cervi- cal cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16INK4a biomarkers. Results: The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Conclusions: Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comprehensive Control of Human Papillomavirus Infections and Related Diseases

  • Bosch José, Francesc Xavier, 1947-
  • Broker, Thomas R.
  • Forman, David
  • Moscicki, Anna-Barbara
  • Gillison, Maura L.
  • Doorbar, John
  • Stern, Peter L.
  • Stanley, Margaret
  • Arbyn, Marc
  • Poljak, Mario
  • Cuzick, Jack
  • Castle, Philip E.
  • Schiller, John T.
  • Markowitz, Lauri E.
  • Fisher, William A.
  • Canfell, Karen
  • Denny, Lynette A.
  • Franco, Eduardo L.
  • Steben, Marc
  • Kane, Mark A.
  • Schiffman, Mark
  • Meijer, Chris J. L. M.
  • Sankaranarayanan, Rengaswamy
  • Castellsagué, Xavier
  • Kim, Jane J.
  • Brotons, Maria
  • Alemany i Vilches, Laia
  • Albero, Ginesa
  • Diaz Sanchis, Mireia
  • Sanjosé Llongueras, Silvia de
Infection with human papillomavirus (HPV) is recognized as one of the major causes of infection-related cancer worldwide, as well as the causal factor in other diseases. Strong evidence for a causal etiology with HPV has been stated by the International Agency for Research on Cancer for cancers of the cervix uteri, penis, vulva, vagina, anus and oropharynx (including base of the tongue and tonsils). Of the estimated 12.7 million new cancers occurring in 2008 worldwide, 4.8% were attributable to HPV infection, with substantially higher incidence and mortality rates seen in developing versus developed countries. In recent years, we have gained tremendous knowledge about HPVs and their interactions with host cells, tissues and the immune system; have validated and implemented strategies for safe and efficacious prophylactic vaccination against HPV infections; have developed increasingly sensitive and specific molecular diagnostic tools for HPV detection for use in cervical cancer screening; and have substantially increased global awareness of HPV and its many associated diseases in women, men, and children. While these achievements exemplify the success of biomedical research in generating important public health interventions, they also generate new and daunting challenges: costs of HPV prevention and medical care, the implementation of what is technically possible, socio-political resistance to prevention opportunities, and the very wide ranges of national economic capabilities and health care systems. Gains and challenges faced in the quest for comprehensive control of HPV infection and HPV-related cancers and other disease are summarized in this review. The information presented may be viewed in terms of a reframed paradigm of prevention of cervical cancer and other HPV-related diseases that will include strategic combinations of at least four major components: 1) routine introduction of HPV vaccines to women in all countries, 2) extension and simplification of existing screening programs using HPV-based technology, 3) extension of adapted screening programs to developing populations, and 4) consideration of the broader spectrum of cancers and other diseases preventable by HPV vaccination in women, as well as in men. Despite the huge advances already achieved, there must be ongoing efforts including international advocacy to achieve widespread optimally universal implementation of HPV prevention strategies in both developed and developing countries. This article summarizes information from the chapters presented in a special ICO Monograph 'Comprehensive Control of HPV Infections and Related Diseases' Vaccine Volume 30, Supplement 5, 2012. Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. (C) 2013 Elsevier Ltd. All rights reserved.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma

  • Baboci, Lorena
  • Boscolo-Rizzo, Paolo
  • Holzinger, Dana
  • Bertorelle, Roberta
  • Biasini, Lorena
  • Michel, Angelika
  • Schmitt, Markus
  • Spinato, Giacomo
  • Bussani, Rossana
  • Alemany i Vilches, Laia
  • Tirelli, Giancarlo
  • Mosto, Maria Cristina Da
  • Mistro, Annarosa Del
  • Pawlita, Michael
Persistent human papillomavirus infection (HPV) is recognized as an important etiologic factor for a subset of head and neck squamous cell carcinomas (SCC), especially those arising from the oropharynx. Whereas HPV16 accounts for the majority of HPV DNA-positive oropharyngeal SCC, infections with other mucosal high-risk HPV types are quite rare and biological data demonstrating their causal involvement are insufficient. Here we present the first case of an oropharyngeal SCC driven by HPV type 58. A 69-year-old Caucasian woman presented with an enlarged and firm left tonsil. A computed tomography scan showed a left tonsillar mass, extending to the soft palate and the glossotonsillar sulcus. The patient underwent extended radical tonsillectomy and ipsilateral selective neck dissection. Pathology confirmed an infiltrating, poorly differentiated SCC of the left tonsil with node metastasis (pT2N1). Adjuvant external beam radiation therapy (60 Grays (Gy)) was administered. After 1 year of follow-up, the patient is well with no evidence of cancer recurrence. HPV analyses of the tumor tissue by BSGP5+/6+-PCR/MPG, targeting 51 mucosal HPV types, showed single positivity for HPV type 58. Presence of HPV58 E6*I RNA demonstrated biological activity of the virus in the tumor tissue, and presence of serum antibodies to HPV58 oncoproteins E6 and E7 indicated presence of an HPV58-driven cancer. Overexpression of cellular protein p16(INK4a) and reduced expression of pRb, two cellular markers for HPV-induced cell transformation, were observed. Exons 4-10 of TP53 showed no mutations or polymorphisms. The presence of HPV58 as single HPV infection in combination with a broad variety of direct and indirect markers of HPV transformation provides comprehensive evidence that this oropharyngeal SCC was driven by HPV58.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Concordance of p16INK4a and E6*I mRNA among HPV-DNA-positive oropharyngeal, laryngeal, and oral cavity carcinomas from the ICO International Study

  • Mena, Marisa
  • Lloveras Rubio, Belen
  • Alemany, Laia
  • International Hpv In Head And Neck Cancer Study Group
Tests or test algorithms for diagnosing HPV-driven oral cavity and laryngeal head and neck carcinomas (HNC) have not been yet validated, and the differences among oral cavity and laryngeal sites have not been comprehensively evaluated. We aimed to assess the utility of a diagnostic algorithm for the detection of HPV-driven oral cavity (OCC), oropharyngeal (OPC) and laryngeal (LC) carcinomas using HPV-DNA testing followed by p16INK4a immunohistochemistry, taking E6*I mRNA detection as the reference standard. Methods: Formalin-fixed paraffin-embedded OCC, OPC, and LC carcinomas were collected from pathology archives in 29 countries. All samples were subjected to histopathological evaluation, DNA quality control, and HPV-DNA detection. All HPV-DNA-positive samples (including 78 OCC, 257 OPC, and 51 LC out of 3680 HNC with valid HPV-DNA results) were also tested for p16INK4a immunohistochemistry and E6*I mRNA. Three different cutoffs of nuclear and cytoplasmic staining were evaluated for p16INK4a: (a) >25%, (b) >50%, and (c) ≥70%. The concordance of p16INK4a and E6*I mRNA among HPV-DNA-positive OCC, OPC, and LC cases was assessed. Results: A total of 78 OCC, 257 OPC, and 51 LC were HPV-DNA-positive and further tested for p16INK4a and E6*I mRNA. The percentage of concordance between p16INK4a (cutoff ≥ 70%) and E6*I mRNA among HPV-DNA-positive OCC, OPC, and LC cases was 79.5% (95% CI 69.9–89.1%), 82.1% (95% CI 77.2–87.0%), and 56.9% (95% CI 42.3–71.4%), respectively. A p16INK4a cutoff of >50% improved the concordance although the improvement was not statistically significant. For most anatomical locations and p16INK4a cutoffs, the percentage of discordant cases was higher for HPV16- than HPV-non16-positive cases. Conclusions: The diagnostic algorithm of HPV-DNA testing followed by p16INK4a immunohistochemistry might be helpful in the diagnosis of HPV-driven OCC and OPC, but not LC. A different p16INK4a expression pattern was observed in those cases HPV-DNA-positive for types other than HPV16, as compared to HPV16-positive cases. Our study provides new insights into the use HPV-DNA, p16INK4a, and HPV-E6*I mRNA for diagnosing an HPV-driven HNC, including the optimal HPV test or p16INK4a cutoffs to be used. More studies are warranted to clarify the role of p16INK4a and HPV status in both OPC and non-OPC HNC., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This study was funded by Instituto de Salud Carlos III through the projects FIS PI081535, FIS PI1102096, FIS PI1102104, and CIBERESP CB06/02/007 (co-funded by European Regional Development Fund (ERDF), a way to build Europe), by the Agència de Gestió d’Ajuts Universitaris I de Recerca AGAUR (2017SGR1085), and by the AECC (Spanish Association Against Cancer). The research leading to these results received funding from the European Union’s Seventh Framework Program (FP7/2007-2013) under grant agreement n◦ HEALTH-F2-2011-282562 HPV-AHEAD, from the Stichting Pathologie Ontwikkeling en Onderzoek (SPOO) foundation (The Netherlands), and from Sanofi Pasteur MSD and Merck & Co, Inc.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer

  • Simoens, Cindy
  • Lloveras Rubio, Belen
  • Arbyn, Marc
  • HPV-AHEAD study group
Background: the incidence of high-risk human papillomavirus (hrHPV)-driven head and neck squamous cell carcinoma, in particular oropharyngeal cancers (OPC), is increasing in high-resource countries. Patients with HPV-induced cancer respond better to treatment and consequently have lower case-fatality rates than patients with HPV-unrelated OPC. These considerations highlight the importance of reliable and accurate markers to diagnose truly HPV-induced OPC. Methods: the accuracy of three possible test strategies, i.e. (a) hrHPV DNA PCR (DNA), (b) p16(INK4a) immunohistochemistry (IHC) (p16), and (c) the combination of both tests (considering joint DNA and p16 positivity as positivity criterion), was analysed in tissue samples from 99 Belgian OPC patients enrolled in the HPV-AHEAD study. Presence of HPV E6*I mRNA (mRNA) was considered as the reference, indicating HPV etiology. Results: ninety-nine OPC patients were included, for which the positivity rates were 36.4%, 34.0% and 28.9% for DNA, p16 and mRNA, respectively. Ninety-five OPC patients had valid test results for all three tests (DNA, p16 and mRNA). Using mRNA status as the reference, DNA testing showed 100% (28/28) sensitivity, and 92.5% (62/67) specificity for the detection of HPV-driven cancer. p16 was 96.4% (27/28) sensitive and equally specific (92.5%; 62/67). The sensitivity and specificity of combined p16 + DNA testing was 96.4% (27/28) and 97.0% (65/67), respectively. In this series, p16 alone and combined p16 + DNA missed 1 in 28 HPV driven cancers, but p16 alone misclassified 5 in 67 non-HPV driven as positive, whereas combined testing would misclassify only 2 in 67. Conclusions: single hrHPV DNA PCR and p16(INK4a) IHC are highly sensitive but less specific than using combined testing to diagnose HPV-driven OPC patients. Disease prognostication can be encouraged based on this combined test result., The global HPV-AHEAD study was initially funded by the European Commission, with Grant Number: FP7-HEALTH-2011-282562. Sciensano, the employer of CS and MA, received funding for the analysis of the Belgian part of the HPV-AHEAD study, in part, by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. MA was also supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network (Grant No. 847845); and the Belgian Foundation Against Cancer through the IHUVACC project.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis

  • Mena Cervigón, Marisa
  • Taberna, Miren
  • Monfil, Laura
  • Arbyn, Marc
  • Sanjosé Llongueras, Silvia de
  • Bosch José, Francesc Xavier, 1947-
  • Alemany i Vilches, Laia
  • Bruni, Laia
Background. Differences in oral human papillomavirus (HPV) prevalence and contrasts in HPV-attributable fractions (AFs) in oropharyngeal cancer (OPC) have not been evaluated in depth. Methods. A systematic review was performed to identify studies in which at least 50 healthy individuals were tested for oral HPV infection. Information on sex, age, tobacco/alcohol consumption, sex practices, specimen collection, HPV detection, and population type was extracted. Prevalences were pooled using random-effects models for meta-analyses of binomial data. Correlations were assessed by the Spearman test. Results. Forty-eight reports comprising 28 544 individuals fulfilled inclusion criteria. Global oral HPV prevalence was 4.9%. Estimates were highest in Europe, although regional differences were not statistically significant. HPV16 prevalence was 1.0% globally, and regional differences became statistically significant. A lifetime history of >6 sex partners showed a higher risk of oral HPV infection. The age-specific HPV distribution revealed a prevalence of >= 5% over 40 years of age and a lower prevalence at younger ages. There was no association between oral HPV prevalence and HPV-AFs or age-standardized rates (ASRs) of OPC, genital HPV in healthy women, or tobacco use. Conclusions. Differences in HPV-AFs or ASRs of OPC cannot be explained by differences in the prevalence of oral HPV infection across healthy populations. Consistent research on determinants of oral HPV prevalence, acquisition, clearance, and persistence is warranted.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study

  • Mena, Marisa
  • Lloveras Rubio, Belen
  • Tous, Sara
  • Bogers, Johannes
  • Maffini, Fausto
  • Gangane, Nitin
  • Kumar, Rekha Vijay
  • Somanathan, Thara
  • Lucas, Eric
  • Anantharaman, Devasena
  • Gheit, Tarik
  • Castellsagué, Xavier
  • Pawlita, Michael
  • Sanjosé Llongueras, Silvia de
  • Alemany, Laia
  • Tommasino, Massimo
  • HPV-AHEAD study group
Worldwide use of formalin-fixed paraffin-embedded blocks (FFPE) is extensive in diagnosis and research. Yet, there is a lack of optimized/standardized protocols to process the blocks and verify the quality and presence of the targeted tissue. In the context of an international study on head and neck cancer (HNC)-HPV-AHEAD, a standardized protocol for optimizing the use of FFPEs in molecular epidemiology was developed and validated. First, a protocol for sectioning the FFPE was developed to prevent cross-contamination and distributed between participating centers. Before processing blocks, all sectioning centers underwent a quality control to guarantee a satisfactory training process. The first and last sections of the FFPEs were used for histopathological assessment. A consensus histopathology evaluation form was developed by an international panel of pathologists and evaluated for four indicators in a pilot analysis in order to validate it: 1) presence/type of tumor tissue, 2) identification of other tissue components that could affect the molecular diagnosis and 3) quality of the tissue. No HPV DNA was found in sections from empty FFPE generated in any histology laboratories of HPV-AHEAD consortium and all centers passed quality assurance for processing after quality control. The pilot analysis to validate the histopathology form included 355 HNC cases. The form was filled by six pathologists and each case was randomly assigned to two of them. Most samples (86%) were considered satisfactory. Presence of >50% of invasive carcinoma was observed in all sections of 66% of cases. Substantial necrosis (>50%) was present in <2% of samples. The concordance for the indicators targeted to validate the histopathology form was very high (kappa > 0.85) between first and last sections and fair to high between pathologists (kappa/pabak 0.21-0.72). The protocol allowed to correctly process without signs of contamination all FFPE of the study. The histopathology evaluation of the cases assured the presence of the targeted tissue, identified the presence of other tissues that could disturb the molecular diagnosis and allowed the assessment of tissue quality., unding Statement This study was supported by the European Commission, grant HPV-AHEAD (FP7-HEALTH-2011-282562), URLs: http://cordis.europa.eu/project/rcn/100268_es.html, All authors, Coordinator MT; Instituto de Salud Carlos III-ISCIII (Spanish Government) cofunded by FEDER funds / European Regional Development Fund (ERDF) - a way to build Europe (Reference: RD12/0036/0056), URLs: http://www.rticc.org/epidemiologia-prevencion-grupos.php#tech, MM, ST, BL, Coordinator Francesc Xavier Bosch.; Instituto de Salud Carlos III-ISCIII (Spanish Government) cofunded by FEDER funds / European Regional Development Fund (ERDF) - a way to build Europe (CIBERESP Group 36 CB06/02/0073), URLs: http://www.ciberesp.es/grupos/grupo-de-investigacion?id=12515, XC and LA, Coordinator SdS; Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR 2014SGR1077), URLs: http://agaur.gencat.cat/en/inici/index.html, XC, LA and ST, Coordinator Francesc Xavier Bosch.; Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR 2014SGR756), URLs: http://agaur.gencat.cat/en/inici/index.html, MM, Coordinator SdS.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Development and validation of a protocol for optimizing the use of paraffin blocks in molecular epidemiological studies: The example from the HPV-AHEAD study

  • Mena Cervigón, Marisa
  • Lloveras Rubio, Betlem
  • Tous, Sara
  • Bogers, Johannes
  • Maffini, Fausto
  • Gangane, Nitin
  • Kumar, Rekha Vijay
  • Somanathan, Thara
  • Lucas, Eric
  • Anantharaman, Devasena
  • Gheit, Tarik
  • Castellsagué, Xavier
  • Pawlita, Michael
  • Sanjosé Llongueras, Silvia de
  • Alemany i Vilches, Laia
  • Tommasino, Massimo
Worldwide use of formalin-fixed paraffin-embedded blocks (FFPE) is extensive in diagnosis and research. Yet, there is a lack of optimized/standardized protocols to process the blocks and verify the quality and presence of the targeted tissue. In the context of an international study on head and neck cancer (HNC)-HPV-AHEAD, a standardized protocol for optimizing the use of FFPEs in molecular epidemiology was developed and validated. First, a protocol for sectioning the FFPE was developed to prevent cross-contamination and distributed between participating centers. Before processing blocks, all sectioning centers underwent a quality control to guarantee a satisfactory training process. The first and last sections of the FFPEs were used for histopathological assessment. A consensus histopathology evaluation form was developed by an international panel of pathologists and evaluated for four indicators in a pilot analysis in order to validate it: 1) presence/type of tumor tissue, 2) identification of other tissue components that could affect the molecular diagnosis and 3) quality of the tissue. No HPV DNA was found in sections from empty FFPE generated in any histology laboratories of HPV-AHEAD consortium and all centers passed quality assurance for processing after quality control. The pilot analysis to validate the histopathology form included 355 HNC cases. The form was filled by six pathologists and each case was randomly assigned to two of them. Most samples (86%) were considered satisfactory. Presence of >50% of invasive carcinoma was observed in all sections of 66% of cases. Substantial necrosis (>50%) was present in <2% of samples. The concordance for the indicators targeted to validate the histopathology form was very high (kappa > 0.85) between first and last sections and fair to high between pathologists (kappa/pabak 0.21-0.72). The protocol allowed to correctly process without signs of contamination all FFPE of the study. The histopathology evaluation of the cases assured the presence of the targeted tissue, identified the presence of other tissues that could disturb the molecular diagnosis and allowed the assessment of tissue quality.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Role of human papillomavirus infection in head and neck cancer in Italy: the HPV-AHEAD study

  • Tagliabue, Marta
  • Lloveras Rubio, Belen
  • Chiocca, Susanna
  • The Hpv-Ahead Study Group
Literature on the role of human papillomavirus (HPV) in head and neck cancer (HNC) in Italy is limited, especially for non-oropharyngeal tumours. Within the context of the HPV-AHEAD study, we aimed to assess the prognostic value of different tests or test algorithms judging HPV carcinogenicity in HNC and factors related to HPV positivity at the European Institute of Oncology. We conducted a retrospective cohort study (2000-2010) on a total of 696 primary HNC patients. Formalin-fixed, paraffin-embedded cancer tissues were studied. All HPV-DNA-positive and a random sample of HPV-DNA-negative cases were subjected to HPV-E6*I mRNA detection and p16INK4a staining. Multivariate models were used to assess for factors associated with HPV positivity and proportional hazards for survival and recurrence. The percentage of HPV-driven cases (considering HPV-E6*I mRNA positivity) was 1.8, 2.2, and 40.4% for oral cavity (OC), laryngeal (LC), and oropharyngeal (OPC) cases, respectively. The estimates were similar for HPV-DNA/p16INK4a double positivity. Being a non-smoker or former smoker or diagnosed at more recent calendar periods were associated with HPV-E6*I mRNA positivity only in OPC. Being younger was associated with HPV-E6*I mRNA positivity in LC. HPV-driven OPC, but not HPV-driven OC and LC, showed better 5 year overall and disease-free survival. Our data show that HPV prevalence in OPC was much higher than in OC and LC and observed to increase in most recent years. Moreover, HPV positivity conferred better prognosis only in OPC. Novel insights on the role of HPV in HNC in Italy are provided, with possible implications in the clinical management of these patients., This study was funded by European Commission HPV-AHEAD. Grant Number: FP7-HEALTH-2011–282562. This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5 × 1000 funds. M. Ar. was supported by the Horizon 2020 Framework Programme for Research and Innovation of the European Commission, through the RISCC Network, Grant Number 847845. Research on HPV and Head and Neck Cancer in Susanna Chiocca laboratory was also supported by Associazione Italiana Ricerca sul Cancro (A.I.R.C. IG 2015 Id.16721).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58

  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Serrano, Beatriz
  • Tous, Sara|||0000-0002-5423-7092
  • Alejo, María
  • Lloveras, Belen|||0000-0001-8659-5241
  • Quiros Blasco, Beatriz|||0000-0002-6187-3732
  • Clavero, Omar|||0000-0001-9721-6382
  • Vidal, August|||0000-0001-5727-2099
  • Ferrandiz-Pulido, Carla|||0000-0003-3688-9596
  • Pavón, Miquel Ángel
  • Holzinger, Dana
  • Halec, Gordana
  • Tommasino, Massimo
  • Quint, Wim
  • Pawlita, Michael
  • Muñoz, Nubia
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Alemany, Laia|||0000-0003-0945-6015
Many countries, mainly high- and upper-middle income, have implemented human papillomavirus (HPV) vaccination programs, with 47 million women receiving the full course of vaccine (three doses) in 2014. To evaluate the potential impact of HPV vaccines in the reduction of HPV-related disease, we aimed to estimate the HPV type distribution and burden of anogenital and head and neck cancers attributable to HPV types (HPVs 16/18/31/33/45/52/58/6/11) included in currently licensed HPV vaccines. In all, 18 247 formalin-fixed paraffin-embedded specimens were retrieved from 50 countries. HPV DNA detection and typing were performed with the SPF-10 PCR/DEIA/LiPA25 system. With the exception of cervical cancer, HPV DNA-positive samples were additionally subjected to HPV E6*I mRNA detection and/or p16 INK4a immunohistochemistry. For cervical cancer, estimates were based on HPV DNA, whereas for other sites, estimates were based on HPV DNA, E6*I mRNA, and p16 INK4a biomarkers. The addition of HPVs 31/33/45/52/58 to HPVs 16/18/6/11 in the nonavalent HPV vaccine could prevent almost 90% of cervical cancer cases worldwide. For other sites, the nonavalent HPV vaccine could prevent 22.8% of vulvar, 24.5% of penile, 60.7% of vaginal, 79.0% of anal cancers, 21.3% of oropharyngeal, 4.0% of oral cavity, and 2.7% of laryngeal cancer cases. Our estimations suggest a potential impact of the nonavalent HPV vaccine in reducing around 90% of cervical cancer cases and a global reduction of 50% of all the cases at HPV-related cancer sites.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Concordance of p16INK4a and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study

  • Mena, Marisa|||0000-0003-2163-892X
  • Wang, Xin
  • Tous, Sara|||0000-0002-5423-7092
  • Quiros Blasco, Beatriz|||0000-0002-6187-3732
  • Clavero, Omar|||0000-0001-9721-6382
  • Alejo, María
  • Morey, Francisca|||0000-0001-5329-9649
  • Taberna, Miren|||0000-0002-2446-186X
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Lloveras Rubio, Belén
  • Alos, Llucìa|||0000-0002-3460-0384
  • Mehanna, Hisham|||0000-0002-5544-6224
  • Quint, Wim
  • Pawlita, Michael
  • Tommasino, Massimo
  • Pavón, Miguel Angel
  • Muñoz, Nubia
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Bosch José, Francesc Xavier|||0000-0002-7172-3412
  • Alemany, Laia|||0000-0003-0945-6015
Background: Tests or test algorithms for diagnosing HPV-driven oral cavity and laryngeal head and neck carcinomas (HNC) have not been yet validated, and the differences among oral cavity and laryngeal sites have not been comprehensively evaluated. We aimed to assess the utility of a diagnostic algorithm for the detection of HPV-driven oral cavity (OCC), oropharyngeal (OPC) and laryngeal (LC) carcinomas using HPV-DNA testing followed by p16 immunohistochemistry, taking E6*I mRNA detection as the reference standard. Methods: Formalin-fixed paraffin-embedded OCC, OPC, and LC carcinomas were collected from pathology archives in 29 countries. All samples were subjected to histopathological evaluation, DNA quality control, and HPV-DNA detection. All HPV-DNA-positive samples (including 78 OCC, 257 OPC, and 51 LC out of 3680 HNC with valid HPV-DNA results) were also tested for p16 immunohistochemistry and E6*I mRNA. Three different cutoffs of nuclear and cytoplasmic staining were evaluated for p16: (a).